BioMarin Pharma (BMRN) Tops Q3 EPS by 4c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $65.51 +1.71%
Revenue Growth %: +32.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $408.7 million versus the consensus estimate of $435.89 million.
GUIDANCE:
BioMarin Pharma sees Q4 2021 revenue of $1.82-1.88 billion, versus the consensus of $1.85 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Copart (CPRT) Misses Q4 EPS by 4c
- RH shares jump after second quarter beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
